During his PhD in Rudolf Jaenisch lab, Alex trained in developmental biology, nuclear transfer and stem cell technology using the mouse as a model system. He also worked extensively on development and disease-related aspects of DNA methylation cialis 20mg hinta . Alex was author and co-author of several papers that demonstrated the conversion of fibroblasts into pluripotent cells by overexpression of defined transcription factors. This field of induced pluripotent stem cells has received wide attention and increases the chances of generating patient-specific stem cells without embryos.
Sam EL – OSTA Baker IDI Institute, AustraliaAssociate Professor Sam El – Osta is a Senior Research Fellow, Head of the Epigenetics in Human Health and Disease Laboratory, and Non-clinical director of the Diabetes Division at the Baker IDI Heart and Diabetes Center Institute. He is director of Epigenomics Profiling Facility and is Associate Professor of Medicine, Monash University. He also has two dates in the Faculty of Medicine at Monash University and the Department of Pathology at the University of Melbourne. His current research is currently. With a series of international and national grants El – Osta has participated recently identified a pathway for sustained activation of genes and proteins in diabetic vascular disease with effects on epigenetic change. Despite great advances in the treatment, diabetes is still the leading cause of new blindness in people 20 to 74 years old, the leading cause of end-stage renal failure, and the leading cause of non – traumatic amputations. His research specifically shows that transient hyperglycemia caused deep epigenetic changes with sustained activation of genes involved in diabetic vascular diseases linked. These findings have profound implications for the treatment of diabetes. Therapies temporary transient hyperglycemic excursions , should significantly reduce the enormous burden of diabetic complications. Characterization of the regulatory complex responsible for persistent epigenetic change and improvement pharmacological inhibitors for continuous improvements induced by hyperglycemia withhold new production targets are to provide end-organ protection products for clinical problems with diabetic vascular complications related services. – – Osta the increasing international profile and research independence by the by the AMGEN Society Australian Medical Researcher of the Year in 2006 and exemplified recently awarded the first Juvenile Diabetes Research Foundation / Macquarie Group Foundation Diabetes Research Innovation Award in 2008 for innovative basic research by exceptional researchers in Australia, the. To search for the prevention and / or a cure for type 1 diabetes and its complications.